

Atty. Dkt.
No.

M#

Client Ref.

056291-5004

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Applicant: Evans et al.

Appln. No.: 09/756,291

Filing Date: January 9, 2001

Date: September 13, 2002

Page 1 of 1

Examiner: Hui, San Ming R.

Group Art Unit: 1617

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR					
	BR					
	CR					
	DR					
	ER					
	FR					
	GR					
	HR					
	IR					

FOREIGN PATENT DOCUMENTS

Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
				Enclosed	No
				No	Enclose
				No	No
JR					
KR					
LR					
MR					
NR					
OR					
PR					
QR					

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

SM	RR	Howell et al., "Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer", The Lancet, Jan. 7, 1995, pp. 29-30
SM	SR	Osborne et al., "Comparison of the Effects of a Pure Steroidal Antiestrogen With Those of Tamoxifen in a Model of Human Breast Cancer", Journal of the National Cancer, May 1995, Vol. 87, No. 10, pp. 746-750
SM	TR	Robertson et al., "A PARTIALLY-BLIND, RANDOMISED, MULTICENTRE STUDY COMPARING THE ANTI-TUMOR EFFECTS OF SINGLE DOSES (50, 125 AND 250MG) OF LONG-ACTING (LA) 'FASLODEX' (ICI 182,780 WITH TAMOXIFIN IN POSTMENOPAUSAL WOMEN WITH PRIMARY BREAST CANCER PRIOR TO SURGERY"; Abstract 28, 22nd Annual San Antonio Breast Cancer Symposium: Dec. 8-11, 1999, San Antonio, Breast Cancer Research and Treatment 1999; 57 (1; special issue); p. 31
	UR	

Examiner

Date Considered: 11/21/02

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.